Search Bar & Filters
Found 15 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating if, for patients with clinically node-positive breast cancer undergoing upfront surgery, treatment with tailored axillary surgery TAS combined with axillary radiotherapy ART is better than axillary lymph node dissection ALND in improving arm-related quality of life QoL and reducing lymphedema two years after treatment. ALND is currently the standard treatment but is associated with major side effects. TAS targets positive lymph nodes more selectively than ALND, potentially causing less harm when combined with ART. The study compares two treatment approaches one group undergoes ALND, the standard surgery removing all lymphatic tissue in the axilla, alongside breast irradiation excluding the axilla the other group receives TAS, which includes sentinel lymph node biopsy and targeted removal of suspicious nodes, combined with breast and axillary radiotherapy ART. All patients receive adjuvant breast irradiation following breast-conserving surgery, with or without axillary radiotherapy depending on their group. The trial follows participants from surgery through post-treatment monitoring. Participants will be assessed from baseline through two years after randomization to monitor changes in arm-related QoL and the occurrence of lymphedema. Researchers will collect quality of life questionnaires and clinical evaluations to measure these outcomes. The study includes randomization into treatment groups and involves regular follow-up to assess long-term effects on arm function and side effects. The overall goal is to determine if TAS plus ART offers improved quality of life compared to ALND.
Actively Recruiting
Researchers are investigating the best approach to treat low-risk patients with isolated subsegmental pulmonary embolism SSPE, a type of blood clot in small lung arteries. The study aims to determine whether monitoring patients without anticoagulation is as safe and effective as giving anticoagulant medication. This is important because many patients currently receive anticoagulants that carry a risk of bleeding, but it is unclear if all patients with isolated SSPE need this treatment. Patients in the trial are randomly assigned to one of two groups. One group receives the anticoagulant drug rivaroxaban, starting with 15 mg twice daily for 21 days, then 20 mg once daily for a total of 90 days. The other group receives a placebo matching the same schedule. The trial compares clinical surveillance without anticoagulation to anticoagulation treatment to assess safety and effectiveness. Participants will be followed for 90 days after randomization to monitor for recurrent venous thromboembolism, significant bleeding events, and overall survival. Researchers will track these outcomes through clinical assessments and safety monitoring. This study is designed to evaluate if careful monitoring alone is a safe alternative to anticoagulation in selected patients with isolated SSPE, potentially reducing bleeding risks from treatment.
Actively Recruiting
Researchers are studying adult patients with unresectable or metastatic HER2-low and HER2-ultralow expressing breast cancer who have either received prior chemotherapy in the metastatic setting or have hormone receptor-positive disease not suitable for endocrine therapy. The study aims to observe the real-world use and effects of Trastuzumab deruxtecan T-DXd and conventional chemotherapy in these populations. This observational study collects data without administering any study drugs directly, focusing on patient characteristics, treatment patterns, and safety. Participants will be grouped into those receiving T-DXd according to approved medical guidelines and those treated with conventional chemotherapy, including drugs like capecitabine and paclitaxel. The study records treatment details and the management of any adverse reactions, with Group 2 patients contributing baseline data on conventional chemotherapy. Treatments are given as part of routine clinical care, following the Summary of Product Characteristics, without experimental interventions. During the study, participants treatment courses will be tracked for up to approximately 37 months. Researchers will evaluate the time to next treatment, treatment discontinuation, safety events, and patients impressions of treatment tolerability and quality of life. Data collection includes physician reports, patient diaries, and quality of life questionnaires. This long-term monitoring helps to understand treatment patterns and patient experiences in real-world settings.
Actively Recruiting
Researchers are evaluating the effectiveness of trastuzumab deruxtecan T-DXd combined with either rilvegostomig or pembrolizumab compared to chemotherapy plus pembrolizumab in treating women with HER2-expressing, mismatch repair proficient, advanced or recurrent endometrial cancer. This Phase III randomized study aims to assess progression-free survival PFS as its primary outcome, with additional measures including overall survival and treatment safety. Participants are assigned to one of three treatment groups Arm A receives T-DXd and rilvegostomig intravenously every three weeks Arm B receives T-DXd and pembrolizumab intravenously every three weeks Arm C receives carboplatin, paclitaxel, and pembrolizumab every three weeks for six cycles followed by pembrolizumab maintenance every six weeks for up to 20 cycles. Treatment continues until disease progression or other discontinuation criteria are met. Docetaxel may replace paclitaxel if necessary due to allergic reactions. During the study, participants will undergo various assessments including imaging to monitor disease progression according to RECIST criteria, safety evaluations, pharmacokinetic and immunogenicity testing, and patient-reported tolerability measures. These assessments occur throughout treatment and up to approximately 70 months for survival and safety follow-up. The study involves regular monitoring by independent review and investigator assessments to evaluate treatment effects and patient outcomes.
Actively Recruiting
Healthy Volunteer
Researchers are studying the PTSD-iMPACT questionnaire, a new tool designed to measure how post-traumatic stress symptoms affect daily functioning in children and adolescents aged 3 to 18 years. The study aims to validate this tool in both clinical and non-clinical populations in Switzerland and Germany. It addresses a need for a reliable, detailed measure of PTSD-related impairments across areas like family, school, friendships, hobbies, and media use. The study involves collecting data from trauma-exposed children, adolescents, and their caregivers through self-report and caregiver-report versions of the PTSD-iMPACT. Participants complete questionnaires at baseline and again two weeks later for test-retest reliability. Data collection occurs in clinical settings and schools, with some assessments completed online or via phonevideo calls. The study is conducted over 13 months and includes both German-speaking clinical populations and a non-clinical sample in Switzerland. Participants provide information on trauma exposure, PTSD symptoms, depression, anxiety, quality of life, and emotional regulation, among other measures. The study uses statistical analyses to assess the reliability and validity of the PTSD-iMPACT tool. Participants in clinical groups complete two assessments, while non-clinical participants complete one. Study involvement includes completing questionnaires online or in person with support provided as needed, ensuring confidentiality and voluntary participation throughout the study.
Actively Recruiting
Researchers are conducting an international, multi-center, randomized, open-label phase III trial to compare elacestrant with standard endocrine therapy in patients with ER-positive, HER2-negative breast cancer who have relapse detected by circulating tumor DNA ctDNA. The study focuses on patients who show ctDNA in their blood but have no distant metastasis, aiming to evaluate treatment outcomes and disease progression. This trial involves a screening phase to monitor ctDNA presence and a randomized treatment phase for eligible patients. During the ctDNA screening phase, patients receive standard adjuvant endocrine therapy, such as tamoxifen or aromatase inhibitors, and undergo plasma testing every six months for up to approximately 5.7 years. Patients who test ctDNA-positive undergo imaging to rule out metastasis and, if eligible, are randomized within four weeks to either continue their current endocrine treatment or receive elacestrant at 400 mg daily orally. Treatment duration varies based on prior endocrine therapy length, lasting between 2 and 7 years. Follow-up includes frequent ctDNA testing and imaging over three years to monitor disease status. Participants will have plasma samples collected regularly during screening and follow-up. Imaging assessments such as mammograms, bone scans, and CT scans are performed to detect metastases or recurrences. Researchers will track distant metastasis-free survival and other outcomes including overall survival, disease recurrence, adverse events, and quality of life over extended periods, up to 11.7 years. The study ensures ongoing monitoring and safety evaluations throughout treatment and follow-up until study completion.
Actively Recruiting
Pelvic Pain Syndrome, specifically Urethral Pain Syndrome UPS, involves persistent or recurring urethral pain without infection or clear cause. This study aims to evaluate the effects of intraurethral and vaginal laser therapy on reducing urethral pressure pain in women with UPS. The research explores a new treatment option because existing therapies often show limited improvement, and laser therapy has shown promise in related gynecological conditions. Participants will receive intraurethral and vaginal laser treatment using the FotonaSmooth ErbiumYAG laser. This is a single-center, prospective pilot study designed to assess the safety and effectiveness of this laser therapy for UPS. The treatment process involves laser application directly to the urethral and vaginal areas, aiming to relieve symptoms and reduce pain. During the study, women will be monitored over several months with assessments including symptom improvement, reduction in tissue induration, pain levels during treatment, infection status, and satisfaction with treatment outcomes. These evaluations will occur at 3, 5, and 12 months after treatment. Participants will complete questionnaires and undergo clinical examinations to track progress and safety, with the total follow-up period extending up to 12 months.
Actively Recruiting
Healthy Volunteer
Researchers are investigating genetic factors linked to Lichen Sclerosus, a skin condition affecting the genital area that can cause itching, pain, and difficulty with daily activities. This condition may be more common in white populations and can involve the skin outside the genital area in some cases. The study focuses on families with members affected by Lichen Sclerosus to understand underlying genetic causes and potentially discover new genes related to the disease. This observational study will collect genome sequencing data from families where some members have Lichen Sclerosus and others do not. By comparing genetic differences within these families, researchers aim to identify new genetic variants associated with the condition. The study is not interventional and does not involve treatments but focuses on genetic analysis over a five-year period. Participants will be family members affected by or related to someone with Lichen Sclerosus. Researchers will analyze genetic samples to identify potential disease-related genes. The main measure is the identification of novel genes linked to Lichen Sclerosus during the study. Participants will be followed for up to five years, contributing genetic data to help advance understanding of the disease and its hereditary factors.
Actively Recruiting
Researchers are evaluating the addition of letrozole, an aromatase inhibitor, to the standard maintenance therapy in women diagnosed with estrogen-receptor ER positive epithelial ovarian cancer, including fallopian tube and primary peritoneal cancer. This study focuses on both low and high grade serous or endometrioid ovarian cancers at FIGO Stage II-IV, whose cancer has not progressed after primary surgery and platinum-based chemotherapy. The main goal is to determine if letrozole can increase progression-free survival compared to the current standard maintenance treatment with placebo. Participants are randomly assigned to receive either letrozole 2.5 mg daily or a placebo tablet once daily for up to five years or until toxicity symptoms or disease progression occur. This randomized, double-blinded, multicenter phase III trial involves 540 eligible women who will be monitored throughout the treatment period. The study also includes a sub-study focusing on low grade ovarian cancer LOGOS. Treatment adherence and tolerability will be assessed during regular visits. Participants will undergo health assessments including blood tests, physical and gynecological exams, and possibly imaging during routine follow-ups every 12 weeks for the first two years, then every 24 weeks for three additional years. Quality of life will be evaluated using specific questionnaires, and participants will wear an activity tracker for one week before visits. Researchers will measure progression-free survival as the primary outcome and also evaluate overall survival, time to next treatment, and quality-adjusted survival. Follow-up data will be collected for up to 12 years, including up to seven years after treatment ends to monitor long-term outcomes.
Actively Recruiting
Researchers are evaluating whether adding detailed tumor and patient-specific biological information improves treatment decisions and outcomes for ovarian cancer patients with homologous recombination proficient HRP or HRD negative tumors. These patients usually have a poor prognosis similar to platinum-resistant cases, and current standard chemotherapy options are limited. The study focuses on personalized treatment recommendations using advanced tumor profiling to guide therapy choices beyond standard care. The study compares two groups one receiving standard chemotherapy with carboplatin and paclitaxel, either every three weeks or weekly, and another receiving treatment recommendations from a molecular tumor board based on a detailed molecular summary report derived from tumor profiling. This report combines multiple precision-cancer profiling methods to identify the most promising drugs or experimental therapies tailored to each patients tumor biology. The trial includes an initial diagnostic phase for HRD testing and tumor profiling, followed by randomization of HRD-negative patients to one of the two treatment approaches. Participants will be closely monitored throughout the study, which lasts about three years including analysis time. Researchers assess how often the tumor board recommends different treatments, how supported oncologists feel by these recommendations, differences in treatment decisions between patients and doctors, and preliminary patient benefits. Patients will undergo regular visits and evaluations to track treatment decisions and outcomes under medical supervision, ensuring safety and adherence to protocols.
1-10 of 15
1